Rochester,NY 8/29/2009 9:35:27 PM
Johnson & Johnson JNJ, strengthens warning on HIV drug
Johnson & Johnson
Johnson & Johnson (JNJ.N) has strengthened a warning about serious skin reactions in patients treated with the company's HIV drug Intelence, U.S. regulators and the company said on Wednesday.
J&J's Tibotec Therapeutics unit updated the warning after reports of one death from a skin reaction known as toxic epidermal necrolysis, and another case of liver failure from a severe reaction and the patient with liver failure recovered later.
Intelence has included a warning about the risk of severe skin reactions since it was launched in January 2008.In clinical trials, the rate of serious skin or allergic reactions was less than 0.1 percent the company said.
About Stock Einstein
StockEinstein uses proprietary technologies coupled with years of experience to uncover stocks we feel have the greatest potential for breakout performance. We utilize not only software, but time tested criteria to uncover these potential winners. When these benchmarks are reached or exceeded, our subscribers are immediately notified.
This service is free and available only to subscribers. Scroll to the bottom of this page to signup for free stock alerts and visit our site.
Disclaimer: Full disclaimer at http://StockEinsteain.com/disclaimer.php
IMPORTANT: Never invest in any stock featured in any press release, email or website unless you can afford the loss of your entire investment. Stocks and particularly penny stocks have the possibility for dramatic gains, and also losses. Neither StockEinsteain, nor any of its affiliates are registered investment advisors or broker dealers.
